Hikma Pharmaceuticals - HIK Share Forecast, Price & News

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Morgan Stanley reiterated an "equal weight" rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, May 11th. Barclays downgraded Hikma Pharmaceuticals to an "equal weight" rating and cut their target price for the company from GBX 2,250 ($27.19) to GBX 1,750 ($21.15) in a research report on Friday, August 5th. Finally, JPMorgan Chase & Co. cut their target price on Hikma Pharmaceuticals from GBX 1,900 ($22.96) to GBX 1,760 ($21.27) and set a "neutral" rating for the company in a research report on Thursday, August 11th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of "Hold" and an average target price of GBX 2,268.33 ($27.41).

Hikma Pharmaceuticals Price Performance

Shares of HIK Stock opened at GBX 1,445 ($17.46) on Friday. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 70.79. Hikma Pharmaceuticals has a twelve month low of GBX 1,424 ($17.21) and a twelve month high of GBX 2,625 ($31.72). The company has a market cap of £3.18 billion and a P/E ratio of 1,162.10. The business has a fifty day simple moving average of GBX 1,628.17 and a 200 day simple moving average of GBX 1,821.03.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, September 19th. Investors of record on Thursday, August 18th will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Thursday, August 18th. This represents a dividend yield of 0.89%. Hikma Pharmaceuticals's dividend payout ratio is currently 41.81%.